FMR LLC raised its holdings in argenx SE – (NASDAQ:ARGX) by 0.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,487,052 shares of the company’s stock after buying an additional 12,003 shares during the quarter. FMR LLC owned 10.84% of argenx worth $335,001,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Northern Trust Corp grew its position in shares of argenx by 11.5% in the 2nd quarter. Northern Trust Corp now owns 12,418 shares of the company’s stock worth $1,029,000 after buying an additional 1,285 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of argenx by 1,715.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 15,429 shares of the company’s stock worth $1,170,000 after buying an additional 14,579 shares during the last quarter. Franklin Resources Inc. grew its position in shares of argenx by 21.9% in the 3rd quarter. Franklin Resources Inc. now owns 600,721 shares of the company’s stock worth $45,559,000 after buying an additional 107,800 shares during the last quarter. Stevens Capital Management LP purchased a new position in shares of argenx in the 3rd quarter worth approximately $214,000. Finally, United Services Automobile Association grew its position in shares of argenx by 88.8% in the 3rd quarter. United Services Automobile Association now owns 60,800 shares of the company’s stock worth $4,611,000 after buying an additional 28,600 shares during the last quarter. 63.73% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ ARGX traded up $3.46 on Friday, hitting $123.88. 74,986 shares of the company’s stock traded hands, compared to its average volume of 179,037. argenx SE – has a 1-year low of $63.81 and a 1-year high of $135.58. The stock has a market cap of $3.85 billion, a price-to-earnings ratio of -52.71 and a beta of 1.23.
WARNING: This article was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/04/26/argenx-se-argx-shares-bought-by-fmr-llc.html.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Further Reading: What is Put Option Volume?
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.